How a Predictive Biosciences Firm Validated Its AI Model Using Expert-Labeled Clinical Narratives
Challenge
A leading predictive biotechnology research company developing AI-powered models for drug toxicity sought to evaluate whether its in silico systems could accurately detect Drug-Induced Liver Injury (DILI) using real-world clinical narratives, 2D molecular structure data, and high-content imaging. However, early model development was hindered by inconsistent image annotations, which introduced ambiguity in key cytotoxic phenotypes such as ER stress and cell death. These inconsistencies limited both the model’s accuracy and its interpretability.
Solution
The organization turned to Cogito Tech to resolve annotation inconsistencies. Our team introduced an iterative annotation workflow, emphasizing area of interest (AOI) segmentation and deep phenotype qualification. Our annotators segmented the project into manageable batches, each informed by feedback loops; our expert annotators helped standardize and boost annotations at scale while aligning tightly with the client’s biological objectives.
Outcome
With each completed batch, the model's performance improved steadily. The outcome of silico DILI predictions now matches or exceeds the accuracy of leading in vitro assays, especially in specificity and interpretability. The project has reached Batch 10, with annotations directly augmenting higher predictive power and reduced false positives. Resulting in a safety/toxicity model with up to 98% accuracy and enhanced interpretability—achieved at a fraction of the cost of traditional 3D liver spheroid assays
From Annotation Ambiguity to AI-Powered Precision
The client initiated their DILI risk model development, and they faced a critical challenge: the vast imaging data from their PHH multiplexed cytotoxicity assays was rich in information but challenging to interpret due to regular annotation of morphological changes. The complexity of cell stress responses, overlapping phenotypes, and visual noise created ambiguity that limited model training efficacy.
Initial Challenges
- Unclear Phenotypic Boundaries: Subtle variations in cell morphology were hard to distinguish and label uniformly.
- Scalability: With over 100,000 molecules to profile, manual annotation without structure risked inconsistency and delay.
- Impact on ML Models: Inconsistent annotations led to noisy training data, impairing the accuracy and interpretability of early in silico models.
Cogito Tech’s Intervention
Cogito deployed a domain-trained annotation team to label 2,000+ clinical records. Annotations captured symptom onset, treatment adjustments, elevated liver enzymes (ALT, AST), and drug discontinuation signals.
1. Discovery & Onboarding
- Aligned with the client’s scientists to comprehend cytotoxicity endpoints and annotation requirements.
- Reviewed sample image sets to spot common areas of confusion and variability.
2. Challenge Assessment
Cogito Tech began by reviewing initial annotated images that revealed inconsistent interpretations of phenotypic features, especially ER stress indicators like cytoplasmic swelling and vesicle formation. These inconsistencies were traced back to vague labeling guidelines and visual complexity in
3. AOI (Area of Interest) Focus
- Narrowed down annotation zones to biologically relevant features (e.g., blebbing, stressed nuclei, vacuolization).
- Removed visual noise and background artifacts to reduce false interpretation by the model.
4. Deep Phenotype Qualification
- Trained annotation teams on domain-specific cytotoxic morphologies.
- Implemented clear annotation protocols and multi-tier quality control to ensure constancy across batches.
5. Annotation Workflow
- AOI Identification – Screening for records mentioning hepatic symptoms or lab values
- Primary Labeling – Event extraction: symptom, drug, liver test result, outcome
- Causality Mapping – Reviewer consensus on suspected DILI linkage
- Quality Assurance – Conflict resolution, calibration, and audit checks
6. Batch-Wise Annotation & Feedback Loop
- The project was divided into numerous batches; each batch underwent review, feedback, and refinement.
- Insights from each batch directly influenced the model’s training, enabling iterative tuning and regular performance gains.
- Current progress: Batch 10 and ongoing.
Result Delivered
With Cogito’s dataset, the client retrained its model and saw a 48% increase in precision, particularly in multi-drug interaction scenarios. Annotator agreement exceeded 92%, ensuring consistency across data labeling phases.
This collaboration remarkably augmented the model’s predictive precision, enabling the client to:
- Discover dose-dependent cell stress patterns more accurately
- Build a DILI risk model outperforming traditional in vitro assays
- Determine model interpretability—crucial for regulatory validation
This partnership illustrates how strategic annotation and high-context curation transform raw imaging data into model-ready, high-confidence training assets. With more batches on the horizon, Cogito Tech supports the client’s mission of reshaping drug safety and accelerating translational science.